Press Releases
We have issued the following announcements related to our business growth and advancements in the areas of liver function health and testing:
2023
2022
- Dec. 5 – Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
- Sep. 12 – Hepion Pharma Announces First Dosing in Phase 2b Clinical Trial with HepQuant Endpoints
- Aug. 24 – HepQuant Lab Meets COLA – CLIA Quality Standards
- May 24 – Preliminary data from the HepQuant SHUNT-V Pivotal study presented at DDW® 2022
- May 10 – Chris Jensen Joins Business Advisory Board
- May 5 – Bobbi Coffin Named to Business Advisory Board
- May 3 – Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
- Feb. 1 – Pharma and Medical Device Veteran Ally Xu Named Director of Regulatory and Quality Affairs
2021
- Nov. 16 – Preliminary data from the HepQuant SHUNT-V Pivotal study released during the 72nd AASLD Annual Meeting
- Nov. 1 – Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health
- April 14 – HepQuant’s Greg Everson, MD, to Speak at AASLD/FDA Conference on Drug-Induced Liver Injury (DILI)
2020
- June 10 – HepQuant Promotes Sean Bundy to Chief Operating Officer
- Feb. 18 – HepQuant to Offer Mobile and Remote Test Administration via CVS Health’s Coram Clinical Trials
- Jan. 10 – HepQuant to Present at Biotech Showcase™ 2020
2019
- Apr. 4 – HepQuant’s Disease Severity Index (DSI) Demonstrates Hepatic Functional Improvement in High Percentage of NASH Patients Treated with Obeticholic Acid: Results from INTERCEPT 747-117
- Feb. 20 – Hoffman Joins HepQuant as Clinical Lab Manager
- Feb. 14 – First Patient Enrolled in a Pivotal Trial of the HepQuant SHUNT Liver Diagnostic Test